Elevated Levels of an Angiogenic Peptide, Basic Fibroblast Growth Factor, in the Urine of Patients With a Wide Spectrum of Cancers
Our results suggest that bFGF in urine deserves further evaluation of its potential use as a monitor of therapy or as a predictor of outcome once a cancer has been diagnosed.